Automate Your Wheel Strategy on TRIB
With Tiblio's Option Bot, you can configure your own wheel strategy including TRIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRIB
- Rev/Share 4.3431
- Book/Share -2.4822
- PB -0.4593
- Debt/Equity -2.8642
- CurrentRatio 1.2813
- ROIC -0.2922
- MktCap 11841293.0
- FreeCF/Share -1.1473
- PFCF -0.7282
- PE -0.5083
- Debt/Assets 0.9755
- DivYield 0
- ROE 1.1176
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”).
Read More
Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity's Broader Profitability and Growth Objectives DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the in-country healthcare product regulatory authority has granted the key approval to initiate offshore and outsourced manufacturing of its flagship World Health Organization (WHO) prequalified TrinScreen™ HIV rapid test. This key …
Read More
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Read More
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
-Trinity Biotech projects it reached Adjusted EBITDA 1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA 1 positive going forward, reflecting continued strong execution on its comprehensive transformation plan.-
Read More
About Trinity Biotech plc (TRIB)
- IPO Date 1992-10-21
- Website https://www.trinitybiotech.com
- Industry Medical - Diagnostics & Research
- CEO John Gillard
- Employees 380